Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
| Market Cap | 7.66M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -10.47M | Forward P/E | -2.43 | EPS next Y | - | 50D Avg Chg | -21.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -65.00% |
| Dividend | N/A | Price/Book | 1.49 | EPS next 5Y | - | 52W High Chg | -87.00% |
| Recommedations | 2.00 | Quick Ratio | 3.58 | Shares Outstanding | 2.52M | 52W Low Chg | 15.00% |
| Insider Own | 21.90% | ROA | -46.55% | Shares Float | 1.23M | Beta | 1.91 |
| Inst Own | 40.09% | ROE | -150.25% | Shares Shorted/Prior | 13.07K/13.51K | Price | 3.18 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 31,312 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 22,805 | Change | 2.25% |
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Cyclerion Therapeutics, Inc. News
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Hecht Peter M | Chief Executive Offi.. Chief Executive Officer | May 06 | Buy | 2.41 | 698,001 | 1,682,182 | 922,528 | 05/06/21 |